AQUESTIVE THERAPEUTICS INC's ticker is AQST and the CUSIP is 03843E104. A total of 47 filers reported holding AQUESTIVE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 2.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $46,053 | -1.7% | 30,100 | +6.0% | 0.00% | – |
| Q2 2023 | $46,860 | +77.9% | 28,400 | +22.9% | 0.00% | – |
| Q1 2023 | $26,334 | -9.9% | 23,100 | -28.7% | 0.00% | – |
| Q4 2022 | $29,228 | -37.8% | 32,400 | -18.8% | 0.00% | – |
| Q3 2022 | $47,000 | +51.6% | 39,900 | -16.7% | 0.00% | – |
| Q2 2022 | $31,000 | -77.4% | 47,900 | -8.6% | 0.00% | – |
| Q1 2022 | $137,000 | -42.9% | 52,400 | -15.2% | 0.00% | -100.0% |
| Q4 2021 | $240,000 | +16.5% | 61,800 | +30.7% | 0.00% | 0.0% |
| Q3 2021 | $206,000 | +42.1% | 47,300 | +29.9% | 0.00% | – |
| Q2 2021 | $145,000 | +150.0% | 36,400 | +225.0% | 0.00% | – |
| Q1 2021 | $58,000 | -31.8% | 11,200 | -36.0% | 0.00% | – |
| Q3 2020 | $85,000 | -26.7% | 17,500 | -26.5% | 0.00% | – |
| Q2 2020 | $116,000 | +205.3% | 23,800 | +37.6% | 0.00% | – |
| Q1 2020 | $38,000 | -40.6% | 17,300 | +57.3% | 0.00% | – |
| Q4 2019 | $64,000 | – | 11,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bratton Capital Management, L.P. | 11,503,294 | $66,949,000 | 80.13% |
| Opaleye Management Inc. | 738,500 | $4,298,000 | 0.84% |
| Wildcat Capital Management, LLC | 455,358 | $2,650,000 | 0.76% |
| One68 Global Capital, LLC | 34,543 | $201,000 | 0.43% |
| Eversept Partners, LP | 350,000 | $2,037,000 | 0.36% |
| Worth Venture Partners, LLC | 94,500 | $550,000 | 0.27% |
| Leap Investments LP | 71,809 | $418,000 | 0.20% |
| Bracebridge Capital, LLC | 428,571 | $2,000,000 | 0.16% |
| Granite Point Capital Management, L.P. | 160,099 | $932,000 | 0.15% |
| True North Advisors, LLC | 32,295 | $187,000 | 0.05% |